

Contents

Section I: Concepts of Drug Resistance

CHAPTER 1

Clinical Setting. J. M. WHITEHOUSE

A. Introduction	3
B. Resistance – A Clinical Phenomenon?	4
C. Disease Assessment	6
D. Drug Selection	9
E. Measurement of Response	11
F. Can Resistance be Quantified Clinically?	13
G. Factors Influencing Changes in Tumour Volume	13
I. Heterogeneous Target Populations of Tumour Cells	13
II. Changes in Histology	14
III. Second Malignancy	15
IV. Miscellaneous Factors Contributing to Tumour Volume	15
H. Influence of Clinically Determined Drug Resistance on Management	16
I. Resistance and Toxicity	16
II. Resistance and Survival	18
References	19

CHAPTER 2

Experimental Setting. J. F. HENDERSON

A. Introduction	23
B. Origins of Resistance	23
I. Changes in the Tumor	23
1. Nongenetic Origins	24
2. Genetic Origins	25
II. Changes in the Host	26
III. Changes in Pharmacological Parameters	27
IV. Experimental Systems	27
C. Mechanisms of Resistance	27
I. Differences in Drug Concentration	28
1. Drug Uptake	28
2. Nucleotide Formation	28
3. Drug Catabolism	29

II. Differences in Drug-Target Interaction	30
1. Drug-Enzyme Binding	30
2. Drug-Cell Interaction	30
3. Metabolite Concentrations	31
III. Differences in Importance of Biochemical Target	31
1. Recovery from Drug Effects	31
2. Alternative Pathways	31
3. Concentration of Target	32
IV. Experimental Systems	32
D. Chemotherapy of Resistant Tumors	34
I. Cross-Resistance	34
II. Collateral Sensitivity	35
III. Circumvention of Resistance	35

Section II: Modification of Host-Tumor Interaction

CHAPTER 3

Drug Disposition and Pharmacology. J. G. McVIE

A. Introduction	39
B. Drug Absorption	41
C. Distribution	47
D. Metabolism	50
E. Renal Excretion	53
F. Dose	54
G. Schedule Dependence	56
H. Drug Interactions	59
J. Conclusion	61
References	61

CHAPTER 4

Immunological Changes. H. FUJI. With 3 Figures

A. Introduction	67
B. Tumor-Associated Antigens	67
C. Altered Transplantability of Drug-Resistant Tumor Sublines	69
I. Tumor Transplantation in Unimmunized Animals	69
II. Tumor Transplantation in Preimmunized Animals	71
III. Adoptive Transfer of Transplantation Immunity	73
D. Immunological Changes in Drug-Resistant Tumor Sublines Defined by Antibodies	73
I. Changes in Tumor Antigenicity Defined by Antisera	73
II. Changes in Tumor Antigenicity Defined by Monoclonal Antibody	76
E. Cellular Immune Responses Against Drug-Resistant Tumor Sublines	78
I. Antibody-Forming Cell Responses	78
II. Cell-Mediated Cytotoxic Responses	78

F. Other Immunobiological Characteristics and Possible Mechanisms of Immunological Changes	79
G. Conclusions	82
References	83

CHAPTER 5

The Molecular Basis of Genetically Acquired Resistance to Purine Analogues in Cultured Mammalian Cells. J. BRENNAND and C. T. CASKEY

A. Introduction	89
B. The HPRT Enzyme	89
C. Biochemical Basis of Drug Resistance	90
D. Drug Resistance as a Consequence of Mutation Within the HPRT Gene	91
I. Phenotypic Variation Resulting from Non-mutational Events	91
II. Evidence that Drug Resistance Results from Mutation Within the HPRT Gene	93
III. Molecular Analysis of the HPRT Gene	94
E. Perspectives	95
References	96

Section III: Cellular Aspects

CHAPTER 6

Cell Cycle Perturbation Effects. B. DREWINKO and B. BARLOGIE. With 14 Figures

A. Introduction	101
I. General	101
II. Proliferating and Quiescent Cells	101
III. Age-Dependent Response	102
IV. Cell Synchronization	102
V. Cell Cycle Perturbation	103
VI. In Vitro Systems	104
VII. Cell Death	105
VIII. Cell Cycle Traverse Rate-Dependent Lethality	105
B. Materials and Methods	106
C. Results	107
I. Proliferating Versus Nonproliferating Cells	107
II. Age-Dependent Survival Response	109
III. Cell Cycle Perturbation	111
1. Asynchronous Cell Populations	111
2. Synchronized Cells	127
IV. Protection of Cell Kill by Inhibition of Cell Cycle Traverse	128
D. Discussion	129
References	136

CHAPTER 7

Tumour Resistance and the Phenomenon of Inflammatory-Cell Infiltration

M. MOORE. With 2 Figures

A. Introduction	143
I. Heterogeneity of Tumour Cells	143
II. Intratumour Lymphoreticular Cells: Biological Implications	144
III. Methodological Approaches	145
B. Characterization of Intratumour Host-Cells	147
I. Total Host-Cell Component	147
II. Criteria for the Identification of Leucocyte Populations and Subpopulations	148
C. Intratumour Leucocytes of Experimental and Human Neoplasms: Descriptive Studies	151
I. Preliminary Considerations	151
II. Nature of Cells Infiltrating Experimental Neoplasms: Biological Correlates	151
III. Nature of Cells Infiltrating Human Neoplasms: Clinicopathological Correlates	156
IV. Factors Which Determine Leucocyte Infiltration of Tumours	161
D. Effector Functions of Intratumour Leucocytes: Experimental Neoplasms	162
I. Systemic Effector Mechanisms	162
II. Macrophage Function	166
III. T-Cell Function	168
IV. Natural Killer Function	169
V. Antibody-Dependent Cellular Cytotoxicity	170
E. Effector Functions of Intratumour Leucocytes: Human Neoplasms	171
I. Macrophage Function	171
II. T-Cell Function	171
III. Natural Killer Function	174
F. Limitations of In Vitro Functional Data	175
G. Implications for Therapy	176
References	178

CHAPTER 8

Flow Cytometric Methods for Studying Enzyme Activity in Populations of Individual Cells.

J. V. WATSON. With 12 Figures

A. Introduction	187
B. Principles of Flow Cytometry	187
C. Enzyme Measurements Using Light Absorption	189
D. Enzyme Measurements Using Fluorogenic Substrates	191
I. Assays with Single Substrates	191
II. Assays Using Two Substrates Simultaneously	200
E. Conclusions	201
References	202

CHAPTER 9

Chromosome Studies. D. SCOTT. With 17 Figures

A. Introduction	205
B. Chromosome Constitution and Resistance	205
I. Derivation of Drug-Resistant Cells	205
II. Resistance to Various Classes of Antitumour Drugs	213
1. Purine Analogues	213
2. Pyrimidine Analogues	216
3. Antifolates	217
4. Alkylating Agents	228
5. Platinum Compounds	229
6. Antibiotics	230
7. <i>Vinca</i> Alkaloids	232
C. Resistance to Induced Chromosome Damage	233
D. Summary	234
References	235

CHAPTER 10

Alterations of Drug Transport. G. J. GOLDENBERG and A. BEGLEITER

A. Introduction	241
B. Mechanism of Drug Transport	241
I. Characteristics of Passive Diffusion and Mediated Transport	241
II. Kinetics of Membrane Transport	242
III. Drug Uptake by Multiple Mechanisms	244
IV. Evaluation of Drug Efflux	245
C. Antitumor Drug Resistance Due to Defects in Membrane Transport	245
I. Alkylating Agents	245
1. Nitrogen Mustard	245
2. Melphalan	250
3. Cyclophosphamide	255
4. Nitrosoureas	256
5. Chlorambucil	257
6. Busulfan	258
7. Procarbazine	258
8. Hexamethylmelamine and Pentamethylmelamine	258
II. Antimetabolites	259
1. Methotrexate	259
2. 6-Mercaptopurine and 6-Thioguanine	263
3. Fluorouracil	265
4. Arabinosylcytosine and Arabinosyladenine	266
III. Antibiotics	267
1. Actinomycin D	267
2. Daunorubicin and Doxorubicin	270
3. Bleomycin	276
4. Mitomycin C	276

IV. Alkaloids	277
1. <i>Vinca</i> Alkaloids	277
2. Colchicine	280
V. Hormones	282
1. Glucocorticoids	282
2. Estrogens	283
3. Androgens and Progestins	283
D. Future Considerations	284
References	286

CHAPTER 11

Cell Hybridisation. J. M. BOYLE. With 5 Figures

A. Introduction	299
B. Cell Fusion In Vivo	301
I. Occurrence of Multinucleate Cells	301
II. Experimental Production of Hybrids In Vivo	304
III. Modified Phenotypes of Hybrids Induced In Vivo	306
C. Use of Drug Resistance for the Selection of Hybrid Clones In Vitro	306
D. Expression of Drug Resistance in Hybrid Cells	310
I. Dominance and Complementation	310
II. Gene Dosage and Functional Hemizygoty	311
III. Multifunctional Enzymes	312
IV. Steroid Resistance and Enzymic Induction by Hormones	314
V. Segregation of Resistance	315
VI. Gene Activation	318
E. Radiation Responses of Hybrid Cells	319
I. Sensitivity to Ionising Radiation and Ultraviolet Light	319
II. Rescue of Genes from Lethally Irradiated Cells	319
F. Conclusions: Possible Therapeutic Implications of Cell Hybridisation	321
References	322

Section IV: Modification of Tumor Biochemistry

CHAPTER 12

Drug Resistance and DNA Repair. M. Fox. With 4 Figures

A. Introduction	335
B. Mechanisms of DNA Repair	336
I. Excision Repair	336
1. Base Modification	337
2. Enzymatic Excision of Base Damage	337
3. Repair of Base Damage	337

4. Nucleotide Excision and Repair	338
5. Influence of Chromatin Structure on DNA Excision Repair	340
II. DNA Synthesis on a Template Containing Unexcised DNA Lesions	342
C. The Relationship Between DNA Repair and Cellular Sensitivity	345
I. Alkylating Agents	345
II. Platinum Compounds	352
III. Mitomycin C	355
IV. Bleomycin	356
D. Cell-Cycle Perturbations and Their Possible Relationships to DNA Repair	358
E. Attempts to Develop Resistance to DNA-Damaging Drugs in Cultured Cell Lines In Vitro	359
F. Conclusions	361
References	362

CHAPTER 13

Cyclic AMP and Prostaglandins. M. J. TISDALE. With 5 Figures

A. Cyclic AMP	371
I. Cyclic AMP and Neoplasia	371
II. Tumour Growth Inhibition by Cyclic AMP and Derivatives	371
III. Role of Cyclic AMP in Regression of Hormone-Dependent Mammary Tumours	373
IV. Role of Cyclic AMP in Growth Inhibition by the Antitumour Alkylating Agents	374
1. Effect on Cyclic AMP Phosphodiesterase	376
2. Effect on Specific Cyclic-AMP-Binding Proteins.	379
3. Alterations in Protein Kinase Activity	381
4. Possible Role of Cyclic AMP in the Cytotoxic Action of Alkylating Agents	382
V. Effect of Other Antitumour Agents on the Cyclic Nucleotide System	382
B. Prostaglandins	383
C. Conclusion	385
References	385

CHAPTER 14

Properties of Mitochondria. A. K. BELOUSOVA. With 4 Figures

A. Introduction	391
B. Damage of Mitochondrial Membranes by Alkylating Agents	391
C. The Structure and Functions of Energy-Coupling Complexes in Mitochondria	392
D. Search for Correlations Between Cell Sensitivity or Resistance to Alkylating Agents and Functional State of Mitochondrial Membranes	394
References	400

CHAPTER 15

Mechanism of "Resistance" Towards Specific Drug Groups. T. A. CONNORS.

With 10 Figures

A. Mechanisms of Alkylation	404
B. Mechanisms of Cytotoxicity and Antitumour Action	406
C. Selectivity of Antitumour Action of the Alkylating Agents	406
D. Patterns of Resistance	407
E. Mechanisms of Resistance	408
I. Resistance Through Decreased Cellular Uptake	409
II. Resistance by Inhibition of the Activation of Prodrugs	413
III. Resistance by Deactivation of Reactive Alkylating Agents	417
IV. Resistance by Interaction with Non-essential Nucleophiles	418
F. Conclusions	420
References	421

CHAPTER 16

Nitrosoureas. K. D. TEW and P. S. SCHEIN

A. Pharmacology	425
B. Mechanisms of Drug Resistance	426
C. Significance of Molecular Considerations	427
D. Monoadducts and Cross-Linking	428
E. Interference with the DNA Repair Process	429
F. Subnucleosomal Nitrosourea Binding	430
G. Effects on Pyridine Nucleotides	431
H. Modulation of Drug Effect with Steroids and Other Transcriptional Modifiers	432
J. Overcoming Resistance to Alkylating Agents with Nitrosoureas	433
K. Clinical Therapeutic Activity	434
L. Conclusions	438
References	439

Section V: Antimetabolites

CHAPTER 17

Antipurines. D.M. TIDD. With 6 Figures

A. Introduction	445
B. 8-Azaguanine	449
I. Metabolism and Mechanism of Action	450
II. Resistance	451
C. 6-Mercaptopurine and 6-Thioguanine	457
I. Metabolism and Mechanism of Action	457
II. Resistance	459

D. 6-Methylthioinosine	466
I. Metabolism and Mechanism of Action	466
II. Resistance	467
E. 9- β -D-Arabinofuranosyladenine	468
I. Metabolism and Mechanism of Action	468
II. Resistance	469
F. Adenine and Adenosine Antipurines	470
I. Metabolism	470
II. Resistance	471
G. Circumvention of Resistance	471
I. Derivatives Metabolized by Alternative Routes	472
II. Potentiation by a Second Agent	473
III. Protected Slow-Release Depot Derivatives	474
IV. Coadministration of Inhibitors of Degradative Enzymes	475
V. Molecular Alteration to Prevent Catabolism but not Anabolism	476
VI. Phosphorylated "Prodrug" Derivatives of Antipurine Nucleotides	478
H. Conclusion	482
References	483

CHAPTER 18

Ribofuranose-containing Analogues of Uridine and Cytidine

A. D. WELCH and N. K. AHMED. With 1 Figure

A. Introduction	495
B. 6-Azauridine	495
I. Another Mechanism for Resistance to 6-Azauridine	499
C. 5-Azacytidine	500
D. Pseudoisocytidine	503
E. 3-Deazauridine	503
F. Concluding Statement	507
References	508

CHAPTER 19

5-Halogenated Pyrimidines and Their Nucleosides

J. A. HOUGHTON and P. J. HOUGHTON. With 2 Figures

A. Introduction	515
B. Metabolism and Mechanism of Action	515
C. Development and Stability	517
D. Transport	519
E. Decreased Lethal Synthesis	520
I. Thymidine Kinase	520
II. Uridine Phosphorylase; Uridine Kinase	521
III. Orotate Phosphoribosyltransferase; Orotidine-5'-Monophosphate Decarboxylase	522

F. Changes in Enzyme Characteristics	523
I. Altered (Mutated) Enzymes	523
II. Increased Enzyme Activities	524
G. Cross-Resistance and Collateral Sensitivity	527
H. Tolerance	527
J. Natural Resistance	527
I. Formation of Nucleotides	528
II. Formation of 5-Fluoro-2'-Deoxyuridylate	528
III. Accumulation of 2'-Deoxyuridylate	529
IV. Concentration of N^5N^{10} -Methylenetetrahydrofolate	529
V. Enzyme Activities	530
VI. Catabolism	531
K. Overcoming Resistance	532
I. Metabolic Modulation	532
1. Naturally Occurring Pyrimidine Metabolites	532
2. Purines and Purine Analogues	533
3. Methotrexate	534
4. Inhibitors of Pyrimidine Biosynthesis de Novo	535
II. Congener Synthesis	536
1. Metabolic Activation	536
2. Decreased Phosphorolytic Cleavage	536
3. Latentiation	537
4. Increased Uptake	537
L. Conclusions	538
References	538

CHAPTER 20

Resistance to Amino Acid Analogs. J. R. UREN. With 2 Figures

A. Definitions	551
B. Natural Resistance	551
C. Acquired and Cross-Resistance	557
I. Glutamine Antagonists	557
1. Biochemistry	557
2. Resistance	558
II. Aspartic Acid Antagonists	559
1. Biochemistry	559
2. Resistance	560
III. Tyrosine Antagonists	561
1. Biochemistry	561
2. Resistance	561
IV. Asparagine Antagonists	561
1. Biochemistry	561
2. Resistance	562
V. General Amino Acid Antagonists	562
1. Biochemistry	562
2. Resistance	563

D. Summary	563
References	564

CHAPTER 21

Alkaloids. W. T. BECK. With 6 Figures

A. Introduction	569
B. Cellular Pharmacology and Biochemistry of the <i>Vinca</i> and <i>Colchicum</i> Alkaloids	571
I. Mechanisms of Alkaloid Accumulation by Cells	571
II. Effects of Alkaloids on Cellular Functions	575
1. Membrane Transport	575
2. Other Membrane-Related Actions	577
3. Cytotoxic Lesions	578
C. Manifestations of Resistance to the Alkaloids	579
I. Resistance and Cross-Resistance Characteristics of Alkaloid- Insensitive Cells	579
II. Pharmacological Bases of Alkaloid Resistance	583
1. Decreased Uptake of Drug	585
2. Diminished Retention of Drug	587
3. Role of Calcium	594
III. Biochemical Alterations Associated with Alkaloid Resistance	595
1. Membrane Alterations	595
2. Cytoplasmic Alterations	600
3. Relationship Between Biochemical Changes and Alkaloid Resistance	601
IV. Genetics of Alkaloid Resistance	602
D. Summary and Future Considerations	605
References	606

Section VI: Antifolates

CHAPTER 22

Folate Antagonists. J. R. BERTINO. With 2 Figures

A. Introduction	615
B. Intrinsic or Natural Resistance to Methotrexate and Other Folate Antagonists	615
C. Acquired Resistance to Folate Antagonists	618
I. Gene Amplification and Elevation of Dihydrofolate Reductase	619
1. Organization of the Dihydrofolate Reductase Gene	620
2. Gene Amplification and Resistance to Other Drugs	621
II. Impaired Transport as a Mechanism of Resistance to Methotrexate	621
III. Altered Dihydrofolate Reductase as a Mechanism of Methotrexate Resistance	622

D. Collateral Sensitivity Between Methotrexate-Resistant Cells and Other Agents	623
E. Overcoming Resistance to Folate Antagonists	623
I. Agents Promoting Methotrexate Transport into Resistant Cells or Tumors	623
II. Effects of Dihydrofolate Reductase or Thymidylate Synthetase Inhibitors on Methotrexate-Resistant Cells	625
III. Methotrexate-Resistant Cells with an Altered Dihydrofolate Reductase as a Target for Inhibitors	625
F. Clinical Studies	625
References	627

CHAPTER 23

Steroids. M. M. IP. With 4 Figures

A. Introduction	633
I. Structure	633
II. Mechanism of Action of Steroid Hormones	634
B. Possible Mechanisms of Steroid Resistance	637
C. S49 Lymphoma and WEHI-7 Thymoma Murine Cell Lines	640
D. The P1798 Mouse Lymphosarcoma	644
E. Human Leukemia	648
F. Breast Cancer	653
I. Estrogen Receptors	653
II. Estrogen and Progesterone Receptors	653
III. Estrogen Resistance	656
IV. Estrogen Receptor and Prognosis	657
V. Estrogen Receptor and Response to Chemotherapy	658
VI. Current and Future Directions in Research	659
G. Conclusions	660
References	661

Section VII: Modification of Resistance

CHAPTER 24

Collateral Sensitivity and Cross-Resistance. B. T. HILL

A. Introduction	673
B. Definition of Terms	674
C. Incidence of Collateral Sensitivity and Cross-Resistance in Experimental Animal Tumours	675
I. In Vivo Studies	675
II. In Vitro Studies	680
D. Mechanisms Implicated in Determining Collateral Sensitivity or Cross-Resistance	681

E. Establishment, Stability and Reversion of Collateral Sensitivity and Cross-Resistance	685
F. Clinical Studies Concerned with the Evaluation of Drug Sensitivity or Cross-Resistance	686
G. Implications of Collateral Sensitivity and Cross-Resistance	689
H. Concluding Remarks	692
References	692
Subject Index	699